Search
Research
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results from a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsMeningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains.
Research
Influenza vaccination in Western Australian children: Exploring the health benefits and cost savings of increased vaccine coverage in childrenTo assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children.
Research
A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis CSafe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma.
Research
Developmental outcomes following vaccine-proximate febrile seizures in childrenTo compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
Vaccine Trials Group with Sir Charles Gairdner Hospital is conducting a trial of a vaccine against Clostridium difficile infection (CDI) in at-risk individuals.
Researchers at The Kids Research Institute Australia are studying a new pneumococcal vaccine designed to provide a broader protection for 21 serotypes of the bacteria S. pneumoniae – 8 more serotypes than the current vaccine given to new babies.
Highlights from the VTG Laboratory in 2024
News & Events
Study finds high RSV awareness with parents open to future immunisationA The Kids Research Institute Australia study designed to gauge community awareness of respiratory syncytial virus (RSV) has found parents and parents-to-be are highly aware of the virus and are open to immunisation to tackle it.
News & Events
Study confirms maternal whooping cough vaccine protects babies at critical ageA The Kids Research Institute Australia and Curtin University-led study has found the maternal whooping cough vaccine given to pregnant mothers in the second or third trimester significantly reduced babies’ risk of infection, protecting them at their most vulnerable age.
News & Events
Latest Deborah Lehmann Research Award RecipientCongratulations to Dr Paula Tesine who is the successful recipient of the Deborah Lehmann Research Award. As the third recipient of the Deborah Lehmann Research Award, Dr Tesine received $30,000 towards her research.